Telmisartan 40 mg + Amlodipine 5 mg Tablets are a combination pharmaceutical formulation containing two active pharmaceutical ingredients in one formulation – a fixed-dose combination. Combining two active ingredients in a single formulation of solid dosage form involves many considerations to ensure product integrity. Formulation design must produce an accurate combination with uniform strength, physically suitable and physically stable.
When combining the two active pharmaceutical ingredients into one product, it is important to evaluate the properties of each active ingredient as well as their physical and chemical properties once mixed in the finished formulation. Developing such a product involves formulation, manufacturing process design and stability assessment.
This combination product is formulated with two active ingredients – Telmisartan 40 mg + Amlodipine 5 mg supported by suitable pharmaceutical excipients selected in accordance with the requirements of the finished dosage form. Such development must take into account the nature of the particulate materials, powder flow, excipient compatibility, compression, dissolution and physical and chemical stability.
For pharmaceutical companies adding a combination product to their portfolio and perhaps expanding into a Pharmaceutical PCD Franchise, this combination may offer a professionally developed solid dosage form. It can also be used as part of a broad portfolio of PCD Pharma Franchise products.
This formulation contains two active pharmaceutical ingredients with very different physic-chemical properties – Telmisartan 40 mg as one component of the formulation and Amlodipine 5 mg as the second component. The strengths of the two active ingredients are carefully controlled and dispensed to maintain the intended dosage strength of the finished product.
It also contains the required quantity of excipients as determined by formulation design; depending on the formulation technology selected, diluents may be used to achieve the final tablet weight, while binders aid cohesiveness in the granule and/or tablets, disintegrants aid tablet breakup, and lubricants and glidants enhance manufacturing performance.
Preformulating testing can be used to evaluate selected excipients with the active ingredients to identify appropriate combinations of excipients and pre-conception formulations, as well as laboratory procedures to prepare the formulation to optimally handle the active pharmaceutical ingredients and ensure homogeneous admixture of each component.
The manufacturing technology used for Telmisartan 40 mg + Amlodipine 5 mg Tablets involves controlled pharmaceutical manufacturing procedures. As well as testing raw materials and issuance, sampling and testing raw materials will occur according to release specifications. Once released, the raw materials are accurately weighed and dispensed onto the formulation according to an officially approved batch formula.
The process selected will be based upon the activity and excipient characteristics and may involve sifting, pre-mixing, granulation, drying, final blending, lubrication and compression. Raw material requirements, technique parameters such as wet and dry granulation, and compression force, machine speed, tooling, tablet weight, compression behavior, powder flow and other parameters are all taken into account to develop the manufacturing process.
The blend uniformity must be carefully controlled to ensure that both active pharmaceutical ingredients are evenly distributed throughout the finished product. Such parameters as powder and tablet flow, as well as thickness, can be tested during the manufacturing process to ensure consistent finished product quality.
The finished tablets may be film-coated depending on the final design of the product. Depending on the product design and final delivery form, coated finished product is also available.
Quality control laboratories are integral to pharmaceutical manufacturing companies. Telmisartan 40 mg + Amlodipine 5 mg Tablets are tested against a defined profile of physical and chemical specifications to assess product suitability and performance.
Standard tests may include assay, disintegration, in-process testing, dissolution, average weight, uniformity of dosage units, friability, hardness, appearance and visual quality and others. Where two active pharmaceutical ingredients are included in the one formulation, suitable analytes are required to be able to identify and quantify each of the active pharmaceutical ingredients.
In-process tests performed at various stages of the manufacturing process can detect variation in blend uniformity, tablet weight, hardness and appearance. Such testing should be fully documented in the batch production record and quality-control data set. Analytical method development may be required to fully characterize both active pharmaceutical ingredients for quality control purposes.
Evaluation of pharmaceutical stability involves systematic assessment of the finished product. Storage stability parameters such as formulation appearance, assay, decomposition products, dissolution and other characteristics are evaluated under a range of controlled environmental conditions to establish product stability.
Depending on the formulation characteristics and finished product design, finished tablets may be individually packaged into blister packages or other suitable packaging configurations to protect the product over its life time. Ideally the finished pack is presented in a similar format to other product containers in the producer's portfolio. The labeling generally describes the product name, formulation contents, strength, expiry date, batch number and other regulatory information.
Finished product presentation via packaging may also be standardized to facilitate product identification. Proper sealing, labeling, production, recording, and inspection contribute to the quality assurance of the finished product.
Using an established combination pharmaceutical in a product portfolio can provide a strong approach to innovative medicine design. The combination pharmaceutical included in a total product portfolio is ideally supported by consistency in manufacturing, analytical testing, product presentation, packaging, labeling and distribution.
A systematic product portfolio with consistently managed product presentation can help form the basis of a PCD Pharma Franchise company – supporting a well-defined and well-known pharmaceutical brand. The quality assurance measures implemented across the portfolio also serve to provide assurance that every finished product represents a known reliability of manufacturing and quality management.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech